Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir
暂无分享,去创建一个
[1] J. Unadkat,et al. Impact of Ignoring Extraction Ratio When Predicting Drug-Drug Interactions, Fraction Metabolized, and Intestinal First-Pass Contribution , 2010, Drug Metabolism and Disposition.
[2] D. Greenblatt,et al. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. , 2009, British journal of clinical pharmacology.
[3] Alex Phipps,et al. Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction , 2009, Drug Metabolism and Disposition.
[4] M Jamei,et al. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. , 2009, Current drug metabolism.
[5] Tristan S. Maurer,et al. A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro , 2008, Drug Metabolism and Disposition.
[6] J. Unadkat,et al. Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors , 2008, Drug Metabolism and Disposition.
[7] P. Zhao. The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo , 2008, Expert opinion on drug metabolism & toxicology.
[8] C. Hughes,et al. Interaction between lopinavir/ritonavir and warfarin , 2007, Canadian Medical Association Journal.
[9] N. Hariparsad,et al. Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions , 2007, Drug Metabolism and Disposition.
[10] Karthik Venkatakrishnan,et al. Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.
[11] E. Kharasch,et al. Simultaneous Measurement of In Vivo P‐glycoprotein and Cytochrome P450 3A Activities , 2006, Journal of clinical pharmacology.
[12] T. Maurer,et al. Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction , 2006, Drug Metabolism and Disposition.
[13] D. Greenblatt,et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir , 2006, Clinical pharmacology and therapeutics.
[14] C. Ernest,et al. Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.
[15] E. Kharasch,et al. Intravenous and oral alfentanil as in vivo probes for hepatic and first‐pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis , 2004, Clinical pharmacology and therapeutics.
[16] R. Zeldin,et al. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.
[17] D. Greenblatt,et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice , 2003, Clinical pharmacology and therapeutics.
[18] D. Greenblatt,et al. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[19] Shiew-Mei Huang,et al. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity , 2001, Clinical pharmacology and therapeutics.
[20] D. Greenblatt,et al. Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir , 2000, Journal of acquired immune deficiency syndromes.
[21] D. Greenblatt,et al. Alprazolam‐ritonavir interaction: Implications for product labeling , 2000, Clinical pharmacology and therapeutics.
[22] G. Plosker,et al. Nelfinavir , 2000, Drugs.
[23] S. Webber,et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[24] P. Vouros,et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[25] J. Leonard,et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects , 1997, Antimicrobial agents and chemotherapy.
[26] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[27] A. D. Rodrigues,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.